Alector to Present at the BTIG Virtual Biotechnology Conference 2020
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm specializing in immuno-neurology, announced that Chief Business Officer Sabah Oney, Ph.D., will speak at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm specializing in immuno-neurology, announced that Chief Business Officer Sabah Oney, Ph.D., will speak at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 11:00 a.m. ET. The event aims to discuss Alector's innovative approaches to treating neurodegenerative diseases by targeting immune dysfunction. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was -2.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET.
A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Contacts
Media
Erica Jefferson
Vice President, Communications and Public Affairs
Alector, Inc.
301-928-4650
erica.jefferson@alector.com
1AB
Dan Budwick
973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.